Bristol Myers Squibb presents first Phase 3 data on KarXT for psychosis in Alzheimer's
FROM THE WIRE · FINANCE.YAHOO.COM
Preliminary findings from the ADEPT-1 12-week open-label lead-in period show observed improvements in hallucination and delusion scores from baseline Preliminary findings from the ADEPT-3 52-week open-label extension provide initial encouraging long-term safety and tolerability…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishPreliminary Phase 3 data on a late-stage drug from a large pharma, potentially relevant for the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The ADEPT-1 study shows improvements in hallucination and delusion scores after the 12-week lead-in period.
- 02The 52-week ADEPT-3 extension provides initial encouraging long-term safety and tolerability data.
- 03The data come from open-label studies and remain preliminary.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets